24/7 Market News Snapshot 04 February, 2025 – Aclarion, Inc. Common Stock (NASDAQ:ACON)

February 4, 2025

DENVER, Colo., 04 February, 2025 (247marketnews.com) – (NASDAQ:ACON) are discussed in this article.
Aclarion, Inc. (ACON) has captured significant attention in the financial markets, witnessing an impressive pre-market boost with shares trading at $10.47, reflecting a remarkable 57.41% increase from the previous closing price of $6.65. This surge is underpinned by substantial investor interest, as evidenced by a trading volume of 1.87 million shares. Such strong market response suggests heightened confidence, potentially driven by Aclarion’s recent advancements in its healthcare initiatives.

Central to this momentum is Aclarion’s achievement in securing nearly $20 million in gross proceeds to fund its pivotal CLARITY trial, a critical step in advancing its innovative Nociscan technology. This prospective, randomized, multicenter clinical trial, overseen by the respected Dr. Nicholas Theodore, intends to prove Nociscan’s efficacy in improving surgical outcomes for patients suffering from chronic low back pain (cLBP). The trial is set to enroll 300 patients across various healthcare facilities, marking an important phase in validating Nociscan’s capability to identify specific lumbar discs that are potential sources of pain.

Utilizing advanced MR Spectroscopy (MRS) alongside augmented intelligence (AI), the Nociscan technology aims to differentiate between painful and nonpainful discs in the lumbar spine. Given the significant global prevalence of degenerative spine disease, affecting approximately 266 million individuals, the findings from this trial could lead to transformative changes in patient diagnostics and treatment strategies.

Ryan Bond, Chief Strategy Officer of Aclarion, highlighted the importance of this funding milestone, stating that it ensures successful completion of the study and positions the company to secure broader payer coverage. As Aclarion pushes the boundaries of healthcare technology, the anticipated outcomes from the CLARITY trial are expected to validate Nociscan’s clinical effectiveness, indicating a significant shift in the management of chronic low back pain.

Related news for (ACON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.